nodes	percent_of_prediction	percent_of_DWPC	metapath
Salbutamol—Sensation of warmth—Hydrochlorothiazide—nephrolithiasis	0.0664	0.0671	CcSEcCtD
Salbutamol—Cardiac murmur—Hydrochlorothiazide—nephrolithiasis	0.0577	0.0583	CcSEcCtD
Salbutamol—Epigastric pain—Hydrochlorothiazide—nephrolithiasis	0.037	0.0374	CcSEcCtD
Salbutamol—Heartburn—Hydrochlorothiazide—nephrolithiasis	0.026	0.0262	CcSEcCtD
Salbutamol—Feeling hot—Hydrochlorothiazide—nephrolithiasis	0.0228	0.023	CcSEcCtD
Salbutamol—Glycosuria—Hydrochlorothiazide—nephrolithiasis	0.0221	0.0223	CcSEcCtD
Salbutamol—Gastrooesophageal reflux disease—Hydrochlorothiazide—nephrolithiasis	0.0198	0.02	CcSEcCtD
Salbutamol—Musculoskeletal pain—Hydrochlorothiazide—nephrolithiasis	0.0181	0.0183	CcSEcCtD
Salbutamol—Wheezing—Hydrochlorothiazide—nephrolithiasis	0.0174	0.0175	CcSEcCtD
Salbutamol—Pulmonary oedema—Hydrochlorothiazide—nephrolithiasis	0.0159	0.0161	CcSEcCtD
Salbutamol—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.0149	0.0151	CcSEcCtD
Salbutamol—Gastroenteritis—Hydrochlorothiazide—nephrolithiasis	0.0147	0.0148	CcSEcCtD
Salbutamol—Nasal congestion—Hydrochlorothiazide—nephrolithiasis	0.0143	0.0144	CcSEcCtD
Salbutamol—Injury—Hydrochlorothiazide—nephrolithiasis	0.0141	0.0143	CcSEcCtD
Salbutamol—Increased appetite—Hydrochlorothiazide—nephrolithiasis	0.0138	0.014	CcSEcCtD
Salbutamol—Atrial fibrillation—Hydrochlorothiazide—nephrolithiasis	0.0137	0.0138	CcSEcCtD
Salbutamol—Affect lability—Hydrochlorothiazide—nephrolithiasis	0.0128	0.0129	CcSEcCtD
Salbutamol—Migraine—Hydrochlorothiazide—nephrolithiasis	0.0128	0.0129	CcSEcCtD
Salbutamol—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.0123	0.0124	CcSEcCtD
Salbutamol—Ataxia—Hydrochlorothiazide—nephrolithiasis	0.0122	0.0123	CcSEcCtD
Salbutamol—Abdominal pain upper—Hydrochlorothiazide—nephrolithiasis	0.0119	0.012	CcSEcCtD
Salbutamol—Hypokalaemia—Hydrochlorothiazide—nephrolithiasis	0.0118	0.0119	CcSEcCtD
Salbutamol—Cramp muscle—Hydrochlorothiazide—nephrolithiasis	0.0117	0.0118	CcSEcCtD
Salbutamol—Abdominal distension—Hydrochlorothiazide—nephrolithiasis	0.0113	0.0114	CcSEcCtD
Salbutamol—Influenza—Hydrochlorothiazide—nephrolithiasis	0.0112	0.0113	CcSEcCtD
Salbutamol—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.0109	0.011	CcSEcCtD
Salbutamol—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.0105	0.0106	CcSEcCtD
Salbutamol—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.0104	0.0105	CcSEcCtD
Salbutamol—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.0101	0.0102	CcSEcCtD
Salbutamol—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.00981	0.0099	CcSEcCtD
Salbutamol—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.00976	0.00985	CcSEcCtD
Salbutamol—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00973	0.00982	CcSEcCtD
Salbutamol—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.00973	0.00982	CcSEcCtD
Salbutamol—Sweating—Hydrochlorothiazide—nephrolithiasis	0.00959	0.00969	CcSEcCtD
Salbutamol—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.00954	0.00963	CcSEcCtD
Salbutamol—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.00944	0.00953	CcSEcCtD
Salbutamol—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.00939	0.00948	CcSEcCtD
Salbutamol—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.00901	0.00909	CcSEcCtD
Salbutamol—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.00894	0.00902	CcSEcCtD
Salbutamol—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.00892	0.009	CcSEcCtD
Salbutamol—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.00838	0.00846	CcSEcCtD
Salbutamol—Flushing—Hydrochlorothiazide—nephrolithiasis	0.00834	0.00842	CcSEcCtD
Salbutamol—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00803	0.0081	CcSEcCtD
Salbutamol—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.00771	0.00778	CcSEcCtD
Salbutamol—Tension—Hydrochlorothiazide—nephrolithiasis	0.00767	0.00775	CcSEcCtD
Salbutamol—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.00766	0.00773	CcSEcCtD
Salbutamol—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.0076	0.00767	CcSEcCtD
Salbutamol—Back pain—Hydrochlorothiazide—nephrolithiasis	0.00757	0.00764	CcSEcCtD
Salbutamol—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00752	0.00759	CcSEcCtD
Salbutamol—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00733	0.0074	CcSEcCtD
Salbutamol—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00726	0.00733	CcSEcCtD
Salbutamol—Agitation—Hydrochlorothiazide—nephrolithiasis	0.00719	0.00726	CcSEcCtD
Salbutamol—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.00715	0.00721	CcSEcCtD
Salbutamol—Malaise—Hydrochlorothiazide—nephrolithiasis	0.00705	0.00712	CcSEcCtD
Salbutamol—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.00703	0.00709	CcSEcCtD
Salbutamol—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00701	0.00708	CcSEcCtD
Salbutamol—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00691	0.00698	CcSEcCtD
Salbutamol—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00687	0.00694	CcSEcCtD
Salbutamol—Cough—Hydrochlorothiazide—nephrolithiasis	0.00682	0.00689	CcSEcCtD
Salbutamol—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.00666	0.00672	CcSEcCtD
Salbutamol—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00666	0.00672	CcSEcCtD
Salbutamol—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.00666	0.00672	CcSEcCtD
Salbutamol—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00664	0.0067	CcSEcCtD
Salbutamol—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.00658	0.00664	CcSEcCtD
Salbutamol—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00651	0.00657	CcSEcCtD
Salbutamol—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00638	0.00644	CcSEcCtD
Salbutamol—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00638	0.00644	CcSEcCtD
Salbutamol—Shock—Hydrochlorothiazide—nephrolithiasis	0.00628	0.00634	CcSEcCtD
Salbutamol—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00623	0.00629	CcSEcCtD
Salbutamol—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00617	0.00623	CcSEcCtD
Salbutamol—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00608	0.00614	CcSEcCtD
Salbutamol—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00596	0.00602	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00582	0.00587	CcSEcCtD
Salbutamol—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00577	0.00583	CcSEcCtD
Salbutamol—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00573	0.00579	CcSEcCtD
Salbutamol—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00569	0.00574	CcSEcCtD
Salbutamol—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00567	0.00573	CcSEcCtD
Salbutamol—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00562	0.00567	CcSEcCtD
Salbutamol—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00555	0.0056	CcSEcCtD
Salbutamol—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.0055	0.00556	CcSEcCtD
Salbutamol—Pain—Hydrochlorothiazide—nephrolithiasis	0.00546	0.00551	CcSEcCtD
Salbutamol—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00546	0.00551	CcSEcCtD
Salbutamol—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00526	0.00531	CcSEcCtD
Salbutamol—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00522	0.00527	CcSEcCtD
Salbutamol—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00507	0.00512	CcSEcCtD
Salbutamol—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00505	0.00509	CcSEcCtD
Salbutamol—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00505	0.00509	CcSEcCtD
Salbutamol—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.0047	0.00475	CcSEcCtD
Salbutamol—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00458	0.00462	CcSEcCtD
Salbutamol—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00452	0.00456	CcSEcCtD
Salbutamol—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00437	0.00441	CcSEcCtD
Salbutamol—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00422	0.00426	CcSEcCtD
Salbutamol—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00406	0.0041	CcSEcCtD
Salbutamol—Rash—Hydrochlorothiazide—nephrolithiasis	0.00402	0.00406	CcSEcCtD
Salbutamol—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00402	0.00406	CcSEcCtD
Salbutamol—Headache—Hydrochlorothiazide—nephrolithiasis	0.004	0.00404	CcSEcCtD
Salbutamol—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00379	0.00383	CcSEcCtD
Salbutamol—ADRB1—Endothelin Pathways—ADCY10—nephrolithiasis	0.0018	0.192	CbGpPWpGaD
Salbutamol—ADRB1—Monoamine GPCRs—CHRM3—nephrolithiasis	0.000748	0.0798	CbGpPWpGaD
Salbutamol—ADRB2—Monoamine GPCRs—CHRM3—nephrolithiasis	0.000732	0.0781	CbGpPWpGaD
Salbutamol—ADRB1—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.000629	0.0671	CbGpPWpGaD
Salbutamol—ADRB2—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.000615	0.0656	CbGpPWpGaD
Salbutamol—ADRB1—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.000459	0.0489	CbGpPWpGaD
Salbutamol—ADRB2—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.000449	0.0479	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Other—CHRM3—nephrolithiasis	0.000325	0.0347	CbGpPWpGaD
Salbutamol—ADRB1—G alpha (s) signalling events—PTH—nephrolithiasis	0.000237	0.0253	CbGpPWpGaD
Salbutamol—ADRB2—G alpha (s) signalling events—PTH—nephrolithiasis	0.000232	0.0248	CbGpPWpGaD
Salbutamol—ADRB1—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.000224	0.0239	CbGpPWpGaD
Salbutamol—ADRB2—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.000219	0.0234	CbGpPWpGaD
Salbutamol—ADRB1—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000144	0.0154	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000141	0.0151	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000124	0.0132	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000121	0.0129	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—RGS14—nephrolithiasis	0.000109	0.0116	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—RGS14—nephrolithiasis	0.000107	0.0114	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	9.93e-05	0.0106	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—RGS14—nephrolithiasis	9.9e-05	0.0106	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—RGS14—nephrolithiasis	9.69e-05	0.0103	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—CHRM3—nephrolithiasis	9.42e-05	0.01	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—CHRM3—nephrolithiasis	9.22e-05	0.00983	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—PTH—nephrolithiasis	8.62e-05	0.00919	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—PTH—nephrolithiasis	8.43e-05	0.00899	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—DGKH—nephrolithiasis	7.37e-05	0.00785	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—DGKH—nephrolithiasis	7.21e-05	0.00768	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ADCY10—nephrolithiasis	6.88e-05	0.00734	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ADCY10—nephrolithiasis	6.73e-05	0.00718	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—DGKH—nephrolithiasis	6.69e-05	0.00713	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—DGKH—nephrolithiasis	6.54e-05	0.00698	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—RGS14—nephrolithiasis	5.85e-05	0.00624	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—RGS14—nephrolithiasis	5.72e-05	0.0061	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—CHRM3—nephrolithiasis	5.33e-05	0.00568	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—CHRM3—nephrolithiasis	5.21e-05	0.00556	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PTH—nephrolithiasis	4.87e-05	0.00519	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CHRM3—nephrolithiasis	4.84e-05	0.00516	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PTH—nephrolithiasis	4.76e-05	0.00508	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CHRM3—nephrolithiasis	4.73e-05	0.00504	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PTH—nephrolithiasis	4.42e-05	0.00472	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PTH—nephrolithiasis	4.33e-05	0.00461	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ATP6V0A4—nephrolithiasis	3.95e-05	0.00421	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—DGKH—nephrolithiasis	3.95e-05	0.00421	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ATP6V0A4—nephrolithiasis	3.87e-05	0.00412	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—DGKH—nephrolithiasis	3.87e-05	0.00412	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CHRM3—nephrolithiasis	2.86e-05	0.00305	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CHRM3—nephrolithiasis	2.79e-05	0.00298	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PTH—nephrolithiasis	2.61e-05	0.00279	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PTH—nephrolithiasis	2.56e-05	0.00273	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GRHPR—nephrolithiasis	2.24e-05	0.00239	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—AGXT—nephrolithiasis	2e-05	0.00213	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—APRT—nephrolithiasis	1.7e-05	0.00181	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	1.7e-05	0.00181	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SPP1—nephrolithiasis	1.31e-05	0.0014	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SPP1—nephrolithiasis	1.28e-05	0.00137	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—AQP1—nephrolithiasis	1.21e-05	0.00129	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CHRM3—nephrolithiasis	1.09e-05	0.00117	CbGpPWpGaD
